Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine

European Journal of Pharmacology

Volumn 353, Issue 1, 1998, Pages 13-21

  Sebens, Jantiena B ^a   Koch, Tineke ^a   Ter Horst, Gert J ^a   Korf, Jakob ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Clozapine; Cross tolerance; Fos protein; Haloperidol; Olanzapine; Tolerance

Indexed keywords

CLOZAPINE; CORTICOSTERONE; HALOPERIDOL; OLANZAPINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTERONE RELEASE; CROSS TOLERANCE; FOREBRAIN; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; CORTICOSTERONE; DRUG TOLERANCE; HALOPERIDOL; MALE; PIRENZEPINE; PROSENCEPHALON; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0031826710     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00391-4     Document Type: Article

References (37)

1. Aoki, C., Go, C.G., Venkatesan, C., Kurose, H., 1994. Perikaryal and synaptic localization of alpha-2A-adrenergic receptor-like immunoreactivity. Brain Res. 650, 181-204.
2. Bealer, S.L., 1993. Histamine releases norepinephrine in the paraventricular nucleus/anterior hypothalamus of the conscious rat. J. Pharmacol. Exp. Ther. 264 (2), 734-738.
3. The olanzapine HGAD study group, Beasley Jr., C.M., Tollefson, G.D., Tran, P., Satterlee, W., Sanger, T., Hamilton, S., 1996. Olanzapine versus placebo and haloperidol, acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
4. Beasley, C.M. Jr., Tollefson, G.D., Tran, P.V., 1997. Efficacy of olanzapine: an overview of pivotal clinical trials. J. Clin. Psychiatry 58 (Suppl. 10), 7-12.
5. Beckstead, R.M., Domesick, V.B., Nauta, W.J., 1979. Efferent connections of the substantia nigra and ventral tegmental area of the rat. Brain Res. 175, 191-217.
6. Bolden, C., Cusack, B., Richelson, E., 1991. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur. J. Pharmacol. 192, 205-206.
7. 2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6, 3177-3188.
8. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P., Wong, D.T., 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
9. Bymaster, F.P., Rasmussen, K., Calligaro, D.O., Nelson, D.L., DeLapp, N.W., Wong, D.T., Moore, N.A., 1997. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J. Clin. Psychiatry 58 (Suppl. 10), 28-36.
10. Carter, D.A., Fibiger, H.C., 1977. Ascending projections of presumed dopamine-containing neurons in the ventral tegmentum of the rat as demonstrated by horseradish peroxidase. Neuroscience 2, 569-576.
11. Casey, D.E., 1997. The relationship of pharmacology to side effects. J. Clin. Psychiatry 58 (Suppl. 10), 55-62.
12. Charnay, Y., Leger, L., Vallet, P.G., Greggio, B., Hof, P.R., Cespuglio, R., Jouvet, M., Bouras, C., 1997. Mapping of 5-HT1a receptor binding sites in the feline brain: a quantitative autoradiographic study using (3H) 8-OH-DPAT. Biogenic Amines 13, 217-232.
13. Coward, D.M., Imperato, A., Urwyler, S., White, T.G., 1989. Biochemical and behavioural properties of clozapine. Psychopharmacology 99, S6-S12.
14. Dawson, R., Kontur, P., Monjan, A., 1984. High-performance liquid chromatographic (HPLC) separation and quantitation of endogenous glucocorticoids after solid-phase extraction from plasma. Horm. Res. 20, 89-94.
15. Deutch, A.Y., Duman, R.S., 1996. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70, 377-389.
16. Deutch, A.Y., Lee, M.C., Iadarola, M.J., 1992. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3, 332-341.
17. 2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37, 287-294.
18. Eaton, M.J., Cheung, S., Moore, K.E., Lookingland, K.J., 1996. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 738, 60-66.
19. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effect. Arch. Gen. Psychiatry 49, 538-544.
20. Fink-Jensen, A., Kristensen, P., 1994. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci. Lett. 182, 115-118.
21. Friedman, L., Knutson, L., Shurell, M., Meltzer, H.Y., 1991. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol. Psychiatry 29, 865-877.
22. Fulton, B., Goa, K.L., 1997. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosis. Drugs 53, 281-298.
23. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., 1988. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796.
24. MacGibbon, G.A., Lawlor, P.A., Bravo, R., Dragunow, M., 1994. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res. 23, 21-32.
25. McGeorge, A.J., Faull, R.L.M., 1989. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29, 503-537.
26. Merchant, K.M., Dobie, D.J., Filloux, F.M., Totzke, M., Aravagiri, M., Dorsa, D.M., 1994. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmacol. Exp. Ther. 271, 460-471.
27. Moore, N.A., Leander, J.D., Benvenga, M.J., Gleason, S.C., Shannon, H., 1997. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J. Clin. Psychiatry 58 (Suppl. 10), 37-44.
28. Nguyen, T.V., Kosofsky, B.E., Birnbaum, R., Cohen, B.M., Hyman, S.E., 1992. Differential expression of c-fos and Zif268 in rat striatum after haloperidol, clozapine and amphetamine. Proc. Natl. Acad. Sci. USA 89, 4270-4274.
29. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16, 1-7.
30. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 124, 148-153.
31. 5 dopamine receptors are expressed in the suprachiasmatic, supraoptic and paraventricular nuclei of primates. Synapse 26, 1-10.
32. Robertson, G.S., Fibiger, H.C., 1992. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
33. Robertson, G.S., Fibiger, H.C., 1996. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 14, 105-110.
34. Robertson, G.S., Matsumara, H., Fibiger, H.C., 1994. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271, 1058-1066.
35. Sebens, J.B., Koch, T., Ter Horst, G.J., Korf, J., 1995. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur. J. Pharmacol. 273, 175-182.
36. Sebens, J.B., Koch, T., Korf, J., 1996. Lack of cross-tolerance between haloperidol and clozapine towards Fos-protein induction in rat forebrain regions. Eur. J. Pharmacol. 315, 269-275.
37. 3) as a novel target for antipsychotics. Biochem. Pharmacol. 43, 659-666.